arrow
M

Mimma Rizzo

azienda ospedaliera universitaria consorziale policlinico di bari
H指数:27
被引数:2,976

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)

基线疾病特征和铂类药物敏感性作为顺铂为基础化疗、阿维鲁姆单抗维持治疗和恩沃利单抗维多汀序贯疗法在晚期尿路上皮癌中的预后预测因素(ARON-2EV研究)

2026-07-290
PRE
Real-world incidence of G3-G4 adverse events with enfortumab vedotin in patients with advanced urothelial carcinoma (ARON-2EV study)
2026-07-290
OA
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study

相对剂量强度对肌肉浸润性尿路上皮癌新辅助化疗中病理完全缓解的影响:一项多中心回顾性研究

2026-07-020
OAAI
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

恩扎卢替尼在转移性激素敏感前列腺癌中的应用:国际、多中心真实世界ARON-3研究的结果

2026-01-080
OAAI
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)

Avelumab维持治疗在晚期尿路上皮癌中的真实世界有效性:来自意大利多中心MALVA研究(Meet-URO 25)的结果

2025-12-010
PRE
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

同源重组修复基因检测变量及前列腺癌患者的诊断路径:一项多中心队列研究

2025-12-010
PRE
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

肾细胞癌辅助性帕博利珠单抗的实证据:多中心真实世界ARON-1研究的结果

2025-11-140
OAAI
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

与毒性相关的免疫治疗停药及结局:接受基于免疫联合治疗方案的晚期肾细胞癌患者(ARON-1研究)

2025-11-040
PRE
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients

纵向验证PROFFIT问卷以评估癌症患者的财务毒性

2025-10-010
OAAI
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset

预后免疫疗法评分(PIS)在经帕博利珠单抗治疗的晚期尿路上皮癌患者中的真实世界数据及ARON-2数据集验证

2025-09-060
PRE
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

帕博利珠单抗联合仑伐替尼在转移性肾细胞癌患者中的应用:国际ARON-1研究的真实世界证据

2025-05-090
OA
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
2025-03-140
OAAI
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

G8老年综合评估筛查和Meet-URO评分在转移性肾细胞癌患者接受一线伊匹木单抗-纳武利尤单抗联合免疫治疗中的预后价值

2025-02-240
OA
Exploring the Impact of the Multimodal CAPABLE eHealth Intervention on Health-Related Quality of Life in Patients With Melanoma Undergoing Immune-Checkpoint Inhibition: Prospective Pilot Study
2025-01-300
OA
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI